Alebund’s AP308 wins FDA clearance for IgA nephropathy trial
AI Summary- Alebund Pharmaceuticals received U.S. FDA clearance for AP308’s IND application.
- Eight weekly doses reduced circulating human IgA and immune complexes approximately 80% versus controls.
- AP308’s clearance moves the candidate from preclinical research into clinical development.